EPA found no unreasonable cancer risk from using laundry detergents like Tide.

1. Concern (minor) Central claims are accurate

   Support or remove "industry has challenged the 2024 determination in court": no cited source mentions a court challenge.

   Summary: using Tide is not a cancer risk by EPA's exposure reviews, though its byproduct 1,4-dioxane is an animal carcinogen and detergent washed down the drain contributes to EPA's drinking-water risk finding. Claim ratings: (1) IARC: inadequate human and sufficient animal evidence, Group 2B: True ("1,4-Dioxane is possibly carcinogenic to humans (Group 2B)"). (2) NTP 'reasonably anticipated': Unverifiable here (PDF unreadable). (3) EPA 2020 found no unreasonable consumer risk from detergents: True ("did not present an unreasonable risk to consumers or bystanders"). (4) The 2024 revision didn't count consumer-use risk: True. (5) Detergents down the drain contribute to drinking-water risk: True. (6) A TSCA section 6 rule to follow: True. (7) 6.1 to 14 ppm (2019) to <1 ppm (January 2024): True (CCE via Newsday). (8) NY limits of 2 ppm/1 ppm and waivers ending December 30, 2025: True (DEC). (9) The 2013 settlement to reformulate below the NSRL: True (As You Sow). (10) No Tide ban in Europe: True (Quint). (11) The central finding, False for the claim about using Tide, at Moderate confidence: Mostly True to True on the cited evidence. (12) "industry has challenged the 2024 determination in court": Unverifiable; hk-summary (Nov 20, 2024) and the EPA page do not mention litigation. Central claims are accurate; one peripheral claim is unsupported, so Minor. Confidence: High on the central claims, Medium overall given the unread PDFs.

   About conclusion, limitation:epa-risk-evaluation, source:hk-summary The finding

2. Concern (minor) Claims are supported and labeled

   Cite a source for "the No Significant Risk Level is a daily dose" and for 'natural' detergents sharing ethoxylated surfactants; neither is in a cited source.

   The central claims each rest on cited evidence, and inferences are labeled ("indicates that manufacturers reduced", "the record does not show which step caused the drop"). The ethoxylation background in the context is supported by cited sources (EPA: "generation of 1,4-dioxane as an ethoxylation process byproduct"; H&K: "produced as a byproduct through ... ethoxylation"). Two peripheral statements have no cited support. limitation:legal-limits says "California's No Significant Risk Level is a daily dose, not a concentration", and the conclusion uses it; asyousow-settlement does not say so. The fifth objection's response says ethoxylated surfactants "appear in many conventional and 'natural' products"; DEC lists indicator ingredients but says nothing about 'natural' products. Both are plausible but stated as fact without a source. Minor. Confidence: High.

   About limitation:legal-limits, conclusion The finding

3. Concern (minor) Sourcing is strong and transparent

   Cite the 2013 Prop 65 consent judgment instead of only As You Sow's account, and credit Newsday as the publisher of cce-2024-testing.

   Central claims rest on primary sources: IARC's monograph summary, EPA's TSCA page, the NY DEC page, and the NY bill. Two lapses. The settlement terms come only from As You Sow, a party to the case, whose page is promotional ("The company's move was widely praised"); the article discloses this, and the filed consent judgment is the primary record. And cce-2024-testing is a Newsday article by Lisa L. Colangelo reposted on CCE's site, but the article presents it as "results published by the testing organization" (method step 4), so it's unclear who published the figures. Neither weakens the rating. Minor. Confidence: Medium.

   About source:asyousow-settlement, source:cce-2024-testing, method:4 The finding

4. Concern (minor) Context is complete

   Explain that EPA's "no unreasonable risk" is a regulatory benchmark, not zero added risk, and add P&G's statement that all Tide shipped in North America meets NY's 1 ppm limit.

   The main contrary evidence is included: animal carcinogenicity, EPA's drinking-water finding (called "the strongest version of the claim"), the 2019 levels, and uncertainty about the settlement. Missing context: (1) "No unreasonable risk" is a regulatory judgement, not a finding of zero risk, and readers seeing the label False may assume the latter. (2) The article does not address whether EPA's consumer finding reflects combined exposure from other products and tap water. (3) The cited Newsday/CCE source quotes P&G that "all product being shipped in North America is compliant with the requirements of the NY 1,4-dioxane statute". This bears directly on limitation:product-testing ("does not establish levels in every Tide variant or market"), but the article leaves it out. None reverses the impression. Minor. Confidence: Medium.

   About conclusion, evidence:epa-risk-evaluation, limitation:product-testing The finding

5. Pass Framing is fair and neutral

   The claim is stated as it circulates, and no one is mocked. The summary gives the counter-evidence prominence ("though it is an animal carcinogen and EPA links detergent washed down the drain to drinking-water risk"). Advocacy (CCE) and industry interests are both flagged. The sources bear out the framing: EPA itself separates consumer use from drinking-water risk. Confidence: High.

6. Pass Uncertainty is stated

   Open questions are stated: the pending EPA rule, unreplicated testing, no epidemiology in detergent users, and "A future rule, new testing, or new human data could change parts of this assessment." Hazard and risk evidence are weighed explicitly, with reasons given. Moderate confidence matches single-agency modeling. Confidence: High.

Coverage: Re-run after the snapshot gzip fix (FactHub issue #279); replaces the earlier run on this version, whose accuracy check was NotChecked. Read archived copies of iarc-vol71, epa-final-risk-evaluation, hk-summary, cce-2024-testing (a Newsday article reposted by CCE), ny-dec-limits, asyousow-settlement and quint-ban-check. Could not read ntp-roc or ny-s4389b (PDFs unsupported), so the NTP-specific statements and the bill number are unverified. Own knowledge was used only to raise questions.

1. Concern (minor) Confidence matches the evidence

   Say that EPA's "no unreasonable risk" means estimated risk below its regulatory benchmark, not zero added risk, so readers don't read False as "no risk at all".

   Moderate confidence fits: the conclusion says it "rests on one agency's modeling, no epidemiological study has directly measured cancer outcomes in detergent users". The title ("EPA found no unreasonable cancer risk from using laundry detergents like Tide.") is accurately attributed. One limitation of some consequence is unstated. "No unreasonable risk" is a regulatory determination that the estimated risk falls below a benchmark, not a finding that use adds no cancer risk. With the label False, a reader may come away believing EPA found zero risk. The article's hazard/risk framing in the context and first objection partly covers this, so Minor.

   About conclusion, evidence:epa-risk-evaluation, limitation:epa-risk-evaluation The finding

2. Concern (minor) Strongest objections answered

   Address whether EPA's consumer-use finding accounts for combined exposure from many 1,4-dioxane-containing products plus tap water, not laundry alone.

   Version 7 answers the main objections with evidence: hazard versus risk, EPA's drinking-water finding (conceded as "the strongest version of the claim"), the European-ban rumor, labeling, and 'natural' detergents. The 2013 settlement versus 2019 levels is now explained in limitation:legal-limits. One secondary objection is unanswered. The article does not address whether EPA's consumer-use finding assessed laundry exposure on its own, or the combined exposure a person gets from many 1,4-dioxane-containing products (dish soap, shampoo, cosmetics) plus contaminated tap water. A skeptic could argue that per-product 'no unreasonable risk' findings understate total exposure. Secondary, so Minor.

   About conclusion, evidence:epa-risk-evaluation The finding

3. Pass Rates the real claim

   The claim is now "Using Tide laundry detergent causes cancer.", which matches how it circulates (personal use of the product) and what the title, answer and editorial note rate. The conclusion stays within that scope and treats the drinking-water pathway as a separate concern ("That is why this article rates the claim about using Tide, and treats the drinking-water pathway as a separate, real concern"). The evidence is U.S.-centric, but Tide is chiefly a North American product and the limitations note the New York-only testing.

4. Pass Rating follows from the evidence

   Reading the evidence before the label, I would rate the narrowed claim False, moderate confidence. EPA's 2020 evaluation found consumer use of laundry products "did not present an unreasonable risk to consumers or bystanders", and the 2024 revision "again did not identify risks to consumers from using these products". The hazard evidence describes high-dose rodent drinking-water studies with "inadequate evidence in humans". The article's label is False, and the conclusion explains why False rather than No evidence ("EPA's exposure modeling is affirmative evidence about people doing laundry, not merely an absence of studies"). The answer agrees with the label.

5. Pass Evidence is independent

   The hazard item no longer claims independence. Its title is now "Two cancer agencies classify...", and its limitation says "Both rest on the same body of rodent drinking-water studies, so they are two reviews of shared evidence rather than two independent lines." The EPA item acknowledges "This line depends on a single agency's modeling", and the conclusion ties Moderate confidence to that dependence. Hazard, EPA risk modelling, product testing and legal limits remain distinct categories, and nothing is presented as more independent than it is.

Coverage: Examined the full article payload of version 7: claim, finding, answer, confidence, title, summary, description, context, keyPoints, conclusion, all four evidence items with methods, institutions, years and limitations, five objections, seven method steps, editorial note and changelog. Source snapshots were not read, per the Skeptic's instructions; evidence was taken as stated.

1. Concern (material) Citations support the evidence

   No cited source says industry challenged EPA's 2024 determination in court (hk-summary predates it); cite the court filing or drop it. NSRL-as-daily-dose is also unsourced.

   Most items are supported. IARC: "inadequate evidence in humans ... sufficient evidence in experimental animals ... possibly carcinogenic to humans (Group 2B)". EPA: consumer use of detergents "did not present an unreasonable risk to consumers or bystanders"; 2024 "does not identify risks to consumers from the use of these products"; detergents "washed down the drain" significantly contribute; "EPA will begin developing a proposed rule under TSCA section 6". CCE: <1 ppm in January 2024, "6.1 ppm to 14 ppm" in 2019. DEC: 2 ppm/1 ppm and "no waiver will be effective after December 30, 2025". As You Sow: the Jan 24, 2013 settlement and nationwide reformulation below the NSRL. Quint: no ban. Two assertions in evidence items are not addressed by any cited source. (1) limitation:epa-risk-evaluation says "The 2024 determination is being challenged in federal court by industry" and attributes the legal timeline partly to a law-firm summary. hk-summary (November 20, 2024) mentions no litigation; it covers the risk determination and the proposed-rule deadline of Nov. 14, 2025. The EPA page doesn't mention a challenge either. The conclusion repeats "industry has challenged the 2024 determination in court." (2) limitation:legal-limits says "California's No Significant Risk Level is a daily dose, not a concentration"; asyousow-settlement does not say this, and the conclusion relies on it. Neither is central to the finding, so the items are partly supported: Material, not Fail. ntp-roc could not be read (PDF).

   About limitation:epa-risk-evaluation, source:hk-summary, limitation:legal-limits, source:asyousow-settlement, conclusion The finding

2. Concern (minor) Sources represented fairly in context

   cce-2024-testing is Newsday's article, which also quotes P&G that all Tide shipped in North America meets NY's limit; name Newsday and note this beside the 'New York only' limitation.

   Context mostly holds. The EPA page confirms the consumer/drinking-water split as the article frames it, and H&K's list of contributing conditions of use ("laundry and dishwashing products") is consistent with EPA's drinking-water rationale. Quint confirms the ban rumor is false and that New York "did not single out Tide". One minor omission: cce-2024-testing is a CCE repost of a Newsday article ("By Lisa L. Colangelo - February 6, 2024"), not a CCE report. The same article quotes P&G: "all product being shipped in North America is compliant with the requirements of the NY 1,4-dioxane statute", and says reformulated product shipped "by the end of 2022". limitation:product-testing says the tests "do not establish levels in every Tide variant or market", and the conclusion says "the record does not show which step caused the drop". The source offers the manufacturer's own statement on both, which a reader should see. This doesn't change the article's impression, so Minor. ntp-roc (PDF) could not be read for context.

   About evidence:product-testing, limitation:product-testing, source:cce-2024-testing The finding

3. Not checked Quotes and figures match

   Every figure checked in a readable source matches. Group 2B (IARC, "VOL. 71 (1999)"). "January 24, 2013" (As You Sow). "6.1 ppm to 14 ppm" in 2019 and "less than 1 part per million" for Tide Original, Persil, Tide Simply Oxi, Gain Original and Dreft Stage 1 Newborn, "analyzed last month" in a Feb 6, 2024 article (CCE/Newsday). "2 ppm ... December 31, 2022, and 1 ppm on December 31, 2023" and "December 30, 2025" (DEC). ECL 35-0105 (DEC). "Published: 08 Feb 2024" (Quint). Not checked: the NTP statements ("reasonably anticipated"; liver tumors in mice, rats and guinea pigs; nasal-cavity cancers in rats; year 2021) and the bill number S4389B, because ntp-roc and ny-s4389b are PDFs FactHub cannot read. (CCE says the law was "approved by state lawmakers in 2019", consistent with the article.)

4. Pass Sources can support their claims

   Each source can support what it is cited for. IARC (inchem.org) and NTP (niehs.nih.gov) are official hazard assessments. EPA's TSCA page is primary for EPA findings. Holland & Knight is an accountable secondary summary. cce-2024-testing is a Newsday news report quoting the testing group, accountable for what the group reported. NY DEC and the NY Senate bill are primary for the limits. As You Sow, a party to the case, is used for its own settlement, and the article discloses this. The Quint's WebQoof is an accountable fact-check desk, used for the ban rumor. No open-edit, satire or opinion source is cited as fact.

5. Pass Conclusion rests on cited evidence

   Every factual assertion in the conclusion traces to an evidence item or its limitation. Hazard: evidence:hazard-classification. EPA 2020/2024 and the drinking-water pathway: evidence:epa-risk-evaluation. Settlement, NSRL and NY limits: evidence:legal-limits. 6.1 to 14 ppm, <1 ppm and no replication: evidence:product-testing. Whether the cited sources back two of those limitation statements (the court challenge, and the NSRL as a daily dose) is reported under citation-supports-evidence and not repeated here.

6. Pass Sources are archived

   All nine sources carry an archiveUrl, and each snapshot reported copy "archive" with HTTP 200.

Coverage: Re-run after the snapshot gzip fix (FactHub issue #279); replaces the earlier run on this version, whose source checks were NotChecked. Read from archived copies: iarc-vol71, epa-final-risk-evaluation, hk-summary, cce-2024-testing (a CCE repost of a Newsday article, Feb 6, 2024), ny-dec-limits, asyousow-settlement, quint-ban-check. Could not read: ntp-roc and ny-s4389b, which are PDFs ("FactHub can't read 'application/pdf' sources yet"). The NTP-specific statements (the 'reasonably anticipated' listing and its tumor sites) and the bill number S4389B are therefore unverified.

1. Concern (minor) Each section does its job

   Add an independence note to the editorial note, e.g. "Evidence spans two countries' agencies, four methods, and work from 1999 to 2024."

   Rule: the article includes a brief independence note (how many countries, methods, and decades are represented). The summary now names the strongest lines ("EPA's 2020 and 2024 exposure-based reviews ... and product tests"), keyPoints state what the evidence establishes, the context is concise framing, and the conclusion synthesizes and weighs the evidence. The editorial note covers scope, caveats and review status but still has no independence note. Version 7's changelog addresses the summary half of the earlier feedback but not this.

   About conclusion The finding

2. Concern (minor) Consistent house style

   Introduce abbreviations at first use: "Environmental Protection Agency (EPA)", "Toxic Substances Control Act (TSCA)", "National Toxicology Program (NTP)".

   Rule: an abbreviation is spelled out at first use. Version 7 fixed IARC, P&G and ppm, but "EPA" is never spelled out in reader-visible text. "TSCA" appears in the conclusion ("EPA's TSCA reviews") and in method step 2 without being tied to "Toxic Substances Control Act", which appears only in the evidence method. "NTP" appears in method step 3 ("the NTP Report on Carcinogens profile") but is never introduced after "U.S. National Toxicology Program". Minor inconsistency: "Prop 65" in limitation:legal-limits versus "Proposition 65" elsewhere. No typos or drafting text found.

   About conclusion, evidence:epa-risk-evaluation, method:2, method:3, limitation:legal-limits The finding

3. Pass Title states the finding

   The title "EPA found no unreasonable cancer risk from using laundry detergents like Tide." states the finding in positive form, names the subject, and resolves the claim without repeating the myth. The seoTitle "Does Tide detergent cause cancer? EPA found no unreasonable risk from using it" uses search wording and states the finding, which the rule allows.

4. Pass Verdict fields agree and stand alone

   Read alone: FactHub rates the claim "Using Tide laundry detergent causes cancer." False (Moderate confidence): "EPA found no unreasonable risk to people using laundry detergents; its 1,4-dioxane concern is contaminated drinking water." The claim is stated as it circulates, not as its correction, and the answer stands alone. The title, summary, description, keyPoints and conclusion all express the same finding in the current label's terms, and no stale "No evidence" wording remains outside the changelog and the conclusion's explanation of the change.

5. Pass Limitations are specific

   Each limitation is specific. Hazard: "two reviews of shared evidence rather than two independent lines", plus dose and dates. EPA: single-agency modeling, location-dependent risk, litigation. Testing: advocacy sponsorship, unnamed lab, no replication. Legal limits: "No Significant Risk Level is a daily dose, not a concentration", and settlement compliance unknown.

6. Pass Tone is measured and respectful

   Language is measured: "indicates that manufacturers reduced the byproduct" (no longer "confirms"), and "the record does not show which step caused the drop". Objections are answered respectfully and with evidence, for example "That is accurate, and it is the strongest version of the claim." No ridicule or unwarranted absolutes.

7. Pass Readers can verify it

   Every source has a role label, full title, description of why it was chosen, and an archive URL. Identifiers are given (IARC Volume 71; NY S4389B). The method steps cover claim definition (1), evidence not resting on one category (2), sources reviewed (3) and recorded limits (6).

Coverage: Examined all reader-visible text of version 7: title, seoTitle, socialTitle, description, claim, answer, summary, keyPoints, context, conclusion, evidence titles/summaries/limitations, objections and responses, method steps, editorial note, image captions and alt text, and source roles, titles and descriptions. Metadata fields were excluded from house-style review. No web or source text used.